动漫精品免费一区二区三区,久久日本三级香港三级,国产亚洲3p一区二区三区,日本一区二区免费看,午夜精品一区二区三区电影 ,99久久成人国产精品免费,国产成人久久精品麻豆二区 ,久久精品这里热有精品,YELLOW视频在线播放,91麻豆精品国产91久久久

Mitral regurgitation (MR) is a common cardiac valve lesion, developing from primary lesions of the mitral valve or secondary to cardiomyopathies. Moderate or higher severity of mitral regurgitation imposes significant volume overload on the left ventricle, causing permanent structural and functional deterioration of the myocardium and heart failure. Since correction of mitral regurgitation can provide symptomatic relief and halt progressive cardiac dysfunction, transcatheter mitral valve repair technologies are emerging as alternative therapies.

Enlight medical is developing transcatheter mitral valve repair and replacement devices, and its repair device NovoClasp^TM is now in the pivotal clinical study in China.